Pfizer PFE
NYSE PFE
$28.58 -0.14 (-0.50%)
As of: Sep 30, 2026 · 3:59 PM EDT

Pfizer (PFE) Non-Current Debt (2009 - 2026)

Updated

Pfizer (PFE) recorded Non-Current Debt of $4.75 billion in Q3 2011, up 212.8% from $1.52 billion a year earlier and up 117.1% from the prior quarter.

Analysis

Pfizer (PFE) Non-Current Debt (2009 - 2026) Analysis & Trends

On a TTM basis, Pfizer's Non-Current Debt came in at $11.13 billion as of Oct 2, 2011.

  • On a year-over-year basis, Non-Current Debt has increased for three consecutive quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 37.34 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 62.48 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -108.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 23.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Bristol Myers Squibb 128.45 Bn 79.72 Bn 9.25 Bn 42.09 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 60.50 Bn
Mar 29, 2026 60.57 Bn
Dec 31, 2025 61.64 Bn
Sep 28, 2025 57.41 Bn
Jun 29, 2025 57.50 Bn
Mar 30, 2025 57.64 Bn
Dec 31, 2024 57.41 Bn
Sep 29, 2024 58.00 Bn
Jun 30, 2024 57.51 Bn
Mar 31, 2024 61.31 Bn
Dec 31, 2023 62.00 Bn
Jul 2, 2023 61.36 Bn
Apr 2, 2023 31.70 Bn
Dec 31, 2022 33.00 Bn
Jul 3, 2022 34.29 Bn
Apr 3, 2022 35.66 Bn
Dec 31, 2021 36.20 Bn
Oct 3, 2021 36.25 Bn
Jul 4, 2021 35.35 Bn
Apr 4, 2021 35.35 Bn
API Access

Pfizer Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=PFE&period=max&api_key=YOUR_API_KEY